Quantity of eligible patients: CDEC discussed the uncertainty in the volume of individuals with moderately intense to significant hemophilia B in Canada suitable for etranacogene dezaparvovec. Clinical professionals consulted by CADTH indicated that some individuals who are categorised as obtaining gentle or average disorder could have a extreme bleeding phenotype, https://hemgenix04826.59bloggers.com/36371129/new-step-by-step-map-for-hemgenix